SCHEMBL25811762

SCHEMBL25811762

Cn1c2c(c3cc(C(=O)NCCN4CCCCC4)ccc31)CCCC2

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.62
MAPT P10636 2/20 0.55
HTR3A P46098 1/20 0.54
MEN1 O00255 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
HPGD P15428 1/20 0.53
ALOX5 P09917 1/20 0.52
PTGS1 P23219 1/20 0.52
PTGS2 P35354 1/20 0.52
PARP1 P09874 1/20 0.51
ALDH1A1 P00352 2/20 0.50
CACNA1G O43497 2/20 0.50
RAD52 P43351 1/20 0.50
POLB P06746 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25815123 0.99 KMT2A (0.61) KMT2AMAPTHTR3AMEN1NPSR1
SCHEMBL25811779 0.97 KMT2A (0.58) KMT2AMAPTHTR3AMEN1NPSR1
SCHEMBL25811754 0.97 KMT2A (0.61) KMT2AMAPTHTR3AMEN1NPSR1
SCHEMBL25812597 0.94 KMT2A (0.58) KMT2AMAPTHTR3AMEN1NPSR1
SCHEMBL25813448 0.94 RAD52 (0.59) KMT2AMAPTHTR3AMEN1NPSR1
SCHEMBL25812566 0.92 KMT2A (0.62) KMT2AMEN1CYP1A2CYP2D6CYP2C9
SCHEMBL25811726 0.91 RAD52 (0.59) KMT2AMAPTHTR3AMEN1NPSR1
SCHEMBL25936813 0.83 ALOX5 (0.52) KMT2AMAPTMEN1ALOX5PTGS1
SCHEMBL25936806 0.82 ALOX5 (0.51) KMT2AMAPTMEN1ALOX5PTGS1
SCHEMBL25811381 0.82 KMT2A (0.78) KMT2AMAPTHTR3AMEN1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES GALYAN BIO INC (US) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES HTT, HYPK, PARK7 KMT2A 981/4885MAPT 18/4885HTR3A 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.